Table 1 Baseline demographics and patient characteristics.

From: Non-infectious uveitis affecting the posterior segment treated with fluocinolone acetonide intravitreal implant: 3-year fellow eye analysis

 

0.2 μg/day FAi-treated eye (n = 59)

Fellow eye (n = 59)

Fisher’s exact probability P two-sided test

Age, mean ± SD, years

48.5 ± 13.97

N/A

Sex, % (n)

61% (36) female, 39% (23) male

N/A

Vitreous haze grade, % eyes (n)

0/0.5+

52.5 (31)

84.7 (50)

0.0003

1/2+

47.5 (28)

15.3 (9)

0.0003

3/4+

0.0 (0)

0.0 (0)

>0.05

Anterior chamber cells grade, % eyes

0/0.5+

91.5 (54)

98.3 (58)

0.207

1 / 2+

8.5 (5)

1.7 (1)

0.207

3 / 4+

0.0 (0)

0.0 (0)

>0.05

BCVA, mean ± SD, ETDRS letters

65.3 ± 17.17

70.6 ± 18.87

0.1133a

IOP, mean ± SD, mmHg

13.4 ± 3.06

14.7 ± 4.26

0.0594a

  1. BCVA best-corrected visual acuity, ETDRS Early Treatment Diabetic Retinopathy Study, FAi fluocinolone acetonide implant, IOP intraocular pressure, N/A not applicable.
  2. aStudent’s t-test.
Back to article page